$1.8B Biotech Sale Targeted In 3 Delaware Class Suits

By Jeff Montgomery (June 14, 2021, 9:12 PM EDT) -- Attorneys for former Emisphere Technologies Inc. stockholders asked Delaware's Chancery Court to consolidate three class suits seeking damages from a $1.8 billion sale of the biotechnology company to Novo Nordisk A/S under terms claimed to have unfairly benefited the company's controlling investors.

The consolidation motion, filed as the second and third suits were unsealed Friday, would unite claims targeting MHR Fund Management LLC, its affiliates and Emisphere directors and officers allegedly beholden to MHR.

Litigation related to Emisphere's December 2020 sale kicked off almost immediately after the deal, although Bernstein Litowitz Berger & Grossmann LLP and its allies appear to have...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!